Platinib (Pujihua) real patient medication feedback and long-term effect analysis

Pralsetinib is a targeted drug targeting RET fusion-positive tumors. It is mainly used to treat RET fusion-positive non-small cell lung cancer (NSCLC) and certain thyroid cancer patients. According to clinical trials and real patient feedback, platinib has significant efficacy in these patient groups. Most patients can observe a reduction in tumor size and improvement in related symptoms, such as dyspnea, cough, or thyroid-related discomfort, early on. Real-world data shows that platinib can still maintain a certain efficacy in patients who have developed resistance after previous chemotherapy or other targeted drug treatment, which provides an important clinical treatment option.

In terms of long-term effects, feedback from some patients shows that platinib can maintain disease stability or partial remission for about a few months to a year. Especially in patients with RET fusion-positive advanced lung cancer, the drug can prolong progression-free survival (PFS) and reduce the risk of rapid disease progression. However, a small number of patients experience reduced efficacy or resistance, which is usually related to the molecular heterogeneity of tumors and individual patient differences. Therefore, regular review of imaging and molecular markers is an important means to ensure that the therapeutic effect is sustained.

Feedback on side effects is generally tolerable by patients. Common adverse reactions include fatigue, diarrhea, hypertension, increased liver function indicators, and thrombocytopenia. Most of these side effects are mild to moderate and can be alleviated by drug dose adjustment or symptomatic treatment. Some patients mentioned that regular monitoring of blood pressure, liver function and blood routine is very necessary. This not only helps with safe medication use, but also helps doctors make balance adjustments between efficacy and safety.

Overall, feedback from real patients shows that platinib has a high efficacy and a controllable safety profile in RET fusion-positive tumors. Long-term use can significantly delay disease progression and improve quality of life, but attention needs to be paid to regular review and side effect management. For patients with drug resistance or obvious side effects, promptly communicate with their doctors to adjust the treatment plan to ensure maximum efficacy and safe medication.

Reference materials:https://www.drugs.com/